Brompton Split Banc Corp T.SBC

Alternate Symbol(s): T.SBC.PR.A

Brompton Split Banc Corp. (the Fund) is a Canada-based mutual fund company. The Fund's investment objectives are to provide holders of Preferred shares with fixed, cumulative, preferential quarterly cash distributions and to return the original issue price of $10.00 per Preferred share to shareholders at maturity and to provide holders of Class A shares with regular monthly cash distributions, targeted to be at least $0.10 per Class A share, and the opportunity for growth in Net Asset Value per Class A share. The Fund invests in a portfolio of common shares of the six Canadian banks. In addition, the Fund may hold up to 10% of the total assets of the portfolio directly in investments in global financial companies or indirectly through exchange-traded funds for the purposes of enhanced diversification and return potential. The Fund's manager is Brompton Funds Limited.

TSX:SBC - Post by User

Brompton Split Banc Corp

<< Previous

Bullboard Posts

Next >>

Post by EdPaquetteon Dec 10, 2020 8:36pm

117 Views

Post# 32085573

Blowout day on its way

FDA Panel Endorses Covid-19 Vaccine; The recommendation paves the way for regulatory agency to grant emergency authorization as early as Friday

Thursday, December 10, 2020, 8:02 PM ET

By Thomas M. Burton and Jared S. Hopkins

A Food and Drug Administration advisory panel recommended approval of the Covid-19 vaccine developed by Pfizer Inc . and BioNTech SE , clearing the way for the FDA to grant emergency authorization of the vaccine as early as Friday.

The approval—by a vote of 17-4 with one abstention after a daylong hearing—came as Covid-19 infections continued surging, claiming about 290,000 American lives.

The disease is now "essentially out of control," Kathrin Jansen , Pfizer 's head of vaccine research and development, told the Vaccines and Related Biological Products Advisory Committee. "Vaccine introduction is an urgent need."

In its vote to approve, the panel said the benefits of the vaccine outweigh the risks for people 16 years of age and older.

"The efficacy is overwhelming" for the vaccine, said Eric Rubin, a Harvard microbiologist, panel member and editor-in-chief of the New England Journal of Medicine. "It's very strong."

"When you have 2,000 to 3,000 people a day—a day—dying of coronavirus, to me this was a clear choice," said Ofer Levy, a panel member and director of the Precision Vaccines Program at Boston Children's Hospital, after the vote.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism